Cargando…

Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia

Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xianbo, Xiao, Feng, Li, Yuan, Qian, Wenbin, Ding, Wei, Ye, Xiujin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291981/
https://www.ncbi.nlm.nih.gov/pubmed/30541583
http://dx.doi.org/10.1186/s13046-018-0976-z
_version_ 1783380320557465600
author Huang, Xianbo
Xiao, Feng
Li, Yuan
Qian, Wenbin
Ding, Wei
Ye, Xiujin
author_facet Huang, Xianbo
Xiao, Feng
Li, Yuan
Qian, Wenbin
Ding, Wei
Ye, Xiujin
author_sort Huang, Xianbo
collection PubMed
description Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and treatment-related resistance. As the majority of chemotherapeutic and targeted drugs kill leukemia cells by triggering apoptosis, the observed resistance indicates the need for novel therapeutic strategies to reactivate nonapoptotic cell death programs in refractory leukemia. Necroptosis is a regulated form of necrosis that is precisely modulated by intracellular signaling pathways and thus provides potential molecular targets for rational therapeutic intervention. Indeed, accumulating evidence indicates that many current antitumor agents can activate necroptotic pathways and thereby induce leukemia cell death. Elucidation of the complete regulatory mechanism of necroptosis is expected to accelerate the development of novel therapeutic strategies for overcoming apoptosis resistance in leukemia. Here, we review the latest research advances in the regulatory mechanisms of necroptosis and summarize the progression of necroptosis-based therapeutic strategies in leukemia.
format Online
Article
Text
id pubmed-6291981
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62919812018-12-17 Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia Huang, Xianbo Xiao, Feng Li, Yuan Qian, Wenbin Ding, Wei Ye, Xiujin J Exp Clin Cancer Res Review Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and treatment-related resistance. As the majority of chemotherapeutic and targeted drugs kill leukemia cells by triggering apoptosis, the observed resistance indicates the need for novel therapeutic strategies to reactivate nonapoptotic cell death programs in refractory leukemia. Necroptosis is a regulated form of necrosis that is precisely modulated by intracellular signaling pathways and thus provides potential molecular targets for rational therapeutic intervention. Indeed, accumulating evidence indicates that many current antitumor agents can activate necroptotic pathways and thereby induce leukemia cell death. Elucidation of the complete regulatory mechanism of necroptosis is expected to accelerate the development of novel therapeutic strategies for overcoming apoptosis resistance in leukemia. Here, we review the latest research advances in the regulatory mechanisms of necroptosis and summarize the progression of necroptosis-based therapeutic strategies in leukemia. BioMed Central 2018-12-12 /pmc/articles/PMC6291981/ /pubmed/30541583 http://dx.doi.org/10.1186/s13046-018-0976-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Huang, Xianbo
Xiao, Feng
Li, Yuan
Qian, Wenbin
Ding, Wei
Ye, Xiujin
Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title_full Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title_fullStr Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title_full_unstemmed Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title_short Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
title_sort bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291981/
https://www.ncbi.nlm.nih.gov/pubmed/30541583
http://dx.doi.org/10.1186/s13046-018-0976-z
work_keys_str_mv AT huangxianbo bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia
AT xiaofeng bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia
AT liyuan bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia
AT qianwenbin bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia
AT dingwei bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia
AT yexiujin bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia